Business & Finance
Altmeyer Named Chairman of AM-Pharma Supervisory Board
7 July 2021 - - Netherlands-based drug developer AM-Pharma B.V. has appointed Mark Altmeyer, MBA, as chairman of its Supervisory Board, the company said.

Altmeyer is a biopharma executive with decades of relevant strategic, operational, and commercial experience.

As chairman of AM-Pharma's Supervisory Board, Altmeyer will provide important guidance as the company expands its global clinical development program and identifies possible future pipeline initiatives for treating serious diseases.

Martijn Kleijwegt, MSc, previous chairman, will remain a member of the AM-Pharma board.

Prior to joining AM-Pharma's Supervisory Board, Mark Altmeyer was founder, president and chief executive officer at Arvelle Therapeutics, in addition to serving as Executive director of Arvelle's board of directors.

At Arvelle, he led the development of the company until its acquisition by Angelini for USD 1bn.

In advance of that transaction, he established Arvelle's global headquarters in Switzerland, secured 200 m initial funding and built the European team to over 100 employees in under two years.

Before Arvelle, Mark served as president and Chief Commercial officer at Axovant Sciences, where he was responsible for establishing Axovant's global commercial capabilities and launch preparations for various pipeline products.

Earlier in his career, Mark served as president and CEO at Otsuka America Pharmaceutical, leading the transformation into a successful commercial organization, doubling total revenues from 2.5 bn to nearly 5 bn in five years.

Mark held senior commercial and business development positions at Bristol-Myers Squibb, Cetus Corp. and Bristol Labs in the United States. He holds an MBA from Harvard Graduate School of Business and a BA in economics from Middlebury College.

AM-Pharma's initial focus is sepsis-associated acute kidney injury, the cause of death for hundreds of thousands of people hospitalized each year.

Its proprietary compound, ilofotase alfa, has the potential to become the first treatment for sepsis-associated acute kidney injury and is now in a global pivotal Phase III clinical trial.